Methyl-[methyl-[methyl(propan-2-yl)phosphoryl]oxyphosphoryl]oxyphosphinic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: Methyl-[methyl-[methyl(propan-2-yl)phosphoryl]oxyphosphoryl]oxyphosphinic acid
• 英文别名: methyl-[methyl-[methyl(propan-2-yl)phosphoryl]oxyphosphoryl]oxyphosphinic acid
• 化学式: C₆H₁₇O₆P₃
• 分子量: 278.12
• InChiKey: LPSPLSUUNPUDEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  89.9
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV<br/>[FR] NUCLÉOSIDES MÉTHYLE OU ALCYNYLE SUBSTITUÉS EN POSITION 3 POUR LE TRAITEMENT DU VIRUS DE L'HÉPATITE C
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2015161137A1

  公开（公告）日：2015-10-22

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3'-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.

  本文提供了用于治疗黄病毒科感染的化合物、组合物和方法，包括HCV感染。在某些实施例中，披露了核苷衍生物的化合物和组合物，可以单独或与其他抗病毒药物联合使用。在某些实施例中，所述化合物是Formula I的3'-取代甲基或炔基核苷衍生物：(I)；或其药学上可接受的盐、溶剂化合物、立体异构体形式、互变异构体形式或多形形式，其中Base、PD、RA、RB1、RB2、RC和Z如本文所定义。
• [EN] 2',4'-BRIDGED NUCLEOSIDES FOR HCV INFECTION<br/>[FR] NUCLÉOSIDES 2', 4'-PONTÉS POUR L'INFECTION PAR LE VHC
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2014066239A1

  公开（公告）日：2014-05-01

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2',4'-bridged nucleosides which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the 2',4'-bridged nucleosides are of Formula 3001:(I) (3001); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, where PD, B, W, X, RA, RB, RC and RD are as described herein.